JP2020522280A5 - - Google Patents

Download PDF

Info

Publication number: JP2020522280A5
Authority: JP; Japan
Prior art keywords: seq; sequence; antibody; antigen; binding fragment
Prior art date: 2018-06-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2020518572A

Other languages

English (en)

Japanese (ja)

Other versions

JP7237950B2 (ja

JP2020522280A (ja

Filing date

2018-06-08

Publication date

2021-07-26

2018-06-08 Application filed filed Critical

2018-06-08 Priority claimed from PCT/EP2018/065239 external-priority patent/WO2018224683A1/en

2020-07-30 Publication of JP2020522280A publication Critical patent/JP2020522280A/ja

2021-07-26 Publication of JP2020522280A5 publication Critical patent/JP2020522280A5/ja

2022-12-20 Priority to JP2022202855A priority Critical patent/JP7467584B2/ja

2023-03-13 Application granted granted Critical

2023-03-13 Publication of JP7237950B2 publication Critical patent/JP7237950B2/ja

Status Active legal-status Critical Current

2038-06-08 Anticipated expiration legal-status Critical

Links

239000012634 fragment Substances 0.000 claims 33
239000000427 antigen Substances 0.000 claims 31
108091007433 antigens Proteins 0.000 claims 31
102000036639 antigens Human genes 0.000 claims 31
238000000034 method Methods 0.000 claims 10
125000003275 alpha amino acid group Chemical group 0.000 claims 8
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 5
206010028980 Neoplasm Diseases 0.000 claims 5
239000000203 mixture Substances 0.000 claims 5
102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 4
201000011510 cancer Diseases 0.000 claims 4
108020004707 nucleic acids Proteins 0.000 claims 4
150000007523 nucleic acids Chemical class 0.000 claims 4
102000039446 nucleic acids Human genes 0.000 claims 4
230000009824 affinity maturation Effects 0.000 claims 2
239000003814 drug Substances 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
239000000546 pharmaceutical excipient Substances 0.000 claims 2
108091023037 Aptamer Proteins 0.000 claims 1
208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
241000283973 Oryctolagus cuniculus Species 0.000 claims 1
206010039509 Scab Diseases 0.000 claims 1
150000001413 amino acids Chemical class 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
238000012258 culturing Methods 0.000 claims 1
229940039227 diagnostic agent Drugs 0.000 claims 1
239000000032 diagnostic agent Substances 0.000 claims 1
229940079593 drug Drugs 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
102000052645 human CD38 Human genes 0.000 claims 1
229940127121 immunoconjugate Drugs 0.000 claims 1
229940124597 therapeutic agent Drugs 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 claims 1

JP2020518572A 2017-06-08 2018-06-08 Ｃｄ３８調節抗体 Active JP7237950B2 (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP2022202855A JP7467584B2 (ja)	2017-06-08	2022-12-20	Ｃｄ３８調節抗体

Applications Claiming Priority (25)

Application Number	Priority Date	Filing Date	Title
US201762517150P	2017-06-08	2017-06-08
US201762517149P	2017-06-08	2017-06-08
US62/517,150		2017-06-08
US62/517,149		2017-06-08
US201762517164P	2017-06-09	2017-06-09
US201762517753P	2017-06-09	2017-06-09
US201762517745P	2017-06-09	2017-06-09
US201762517165P	2017-06-09	2017-06-09
US201762517734P	2017-06-09	2017-06-09
US201762517740P	2017-06-09	2017-06-09
US62/517,745		2017-06-09
US62/517,164		2017-06-09
US62/517,740		2017-06-09
US62/517,753		2017-06-09
US62/517,734		2017-06-09
US62/517,165		2017-06-09
US201762582676P	2017-11-07	2017-11-07
US201762582666P	2017-11-07	2017-11-07
US201762582681P	2017-11-07	2017-11-07
US201762582653P	2017-11-07	2017-11-07
US62/582,666		2017-11-07
US62/582,653		2017-11-07
US62/582,681		2017-11-07
US62/582,676		2017-11-07
PCT/EP2018/065239 WO2018224683A1 (en)	2017-06-08	2018-06-08	Cd38 modulating antibody

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2022202855A Division JP7467584B2 (ja)	2017-06-08	2022-12-20	Ｃｄ３８調節抗体

Publications (3)

Publication Number	Publication Date
JP2020522280A JP2020522280A (ja)	2020-07-30
JP2020522280A5 true JP2020522280A5 (2)	2021-07-26
JP7237950B2 JP7237950B2 (ja)	2023-03-13

Family

ID=62620847

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
JP2020518573A Active JP7237951B2 (ja)	2017-06-08	2018-06-08	Ｃｄ３８調節抗体
JP2020518572A Active JP7237950B2 (ja)	2017-06-08	2018-06-08	Ｃｄ３８調節抗体
JP2022202855A Active JP7467584B2 (ja)	2017-06-08	2022-12-20	Ｃｄ３８調節抗体

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
JP2020518573A Active JP7237951B2 (ja)	2017-06-08	2018-06-08	Ｃｄ３８調節抗体

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2022202855A Active JP7467584B2 (ja)	2017-06-08	2022-12-20	Ｃｄ３８調節抗体

Country Status (8)

Country	Link
US (3)	US12343394B2 (2)
EP (2)	EP3635002A1 (2)
JP (3)	JP7237951B2 (2)
KR (3)	KR102719065B1 (2)
CN (2)	CN110997722B (2)
AU (3)	AU2018280871B2 (2)
CA (2)	CA3066553A1 (2)
WO (2)	WO2018224685A1 (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102719065B1 (ko)	2017-06-08	2024-10-17	블랙 벨트 테라퓨틱스 리미티드	Cd38 조정 항체
SG11202000321PA (en)	2017-08-16	2020-02-27	Black Belt Therapeutics Ltd	Cd38 modulating antibody
CN110144008B (zh) *	2018-02-12	2021-03-19	杭州尚健生物技术有限公司	Cd38蛋白抗体及其应用
US20200345725A1 (en)	2019-01-11	2020-11-05	Omeros Corporation	Methods and Compositions for Treating Cancer
CN113614107A (zh) *	2019-01-23	2021-11-05	Encefa公司	Cd31竞争剂及其用途
WO2020185859A1 (en)	2019-03-12	2020-09-17	Arcus Biosciences, Inc.	Treatment of oncogene-driven cancers
US12310965B2 (en)	2019-03-29	2025-05-27	Arcus Biosciences, Inc.	Treatment of cancer utilizing an identified adenosine fingerprint
JP7555953B2 (ja) *	2019-03-29	2024-09-25	ソレント・セラピューティクス・インコーポレイテッド	Ｃｄ３８に結合する操作されたバリアント抗体
US12181485B2 (en)	2020-09-10	2024-12-31	CASI Pharmaceuticals, Inc	Methods of blood screening
CN114457028A (zh) *	2020-10-30	2022-05-10	未来智人再生医学研究院(广州)有限公司	一种表达cd38抗体的多能干细胞及其衍生物与应用
CN114437215B (zh) *	2020-11-05	2023-02-07	上海麦济生物技术有限公司	抗人cd38抗体及其制备方法和用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020164788A1 (en) *	1994-12-02	2002-11-07	The Wellcome Foundation Limited	Humanized antibodies to CD38
US20030148321A1 (en) *	2001-08-24	2003-08-07	Iris Pecker	Methods and kits for diagnosing and monitoring hematopoietic cancers
AU2011202520C1 (en)	2002-10-17	2016-02-18	Genmab A/S	Human monoclonal antibodies against CD20
US8039218B2 (en) *	2002-11-14	2011-10-18	John Wayne Cancer Institute	Detection of cancer cells in body fluids
US8263746B2 (en)	2004-02-06	2012-09-11	Morphosys Ag	Anti-CD38 human antibodies and uses thereof
DK2511297T3 (en)	2004-02-06	2015-06-15	Morphosys Ag	Human anti-CD38 antibodies and their applications
US9200061B2 (en)	2004-02-06	2015-12-01	Morpho Sys AG	Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
EP2567976B1 (en) *	2005-03-23	2017-07-19	Genmab A/S	Antibodies against CD38 for treatment of multiple myeloma
WO2006113747A2 (en) *	2005-04-19	2006-10-26	Prediction Sciences Llc	Diagnostic markers of breast cancer treatment and progression and methods of use thereof
TW200745162A (en)	2005-05-24	2007-12-16	Morphosys Ag	Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
EP2860192B1 (en)	2005-10-12	2017-09-27	MorphoSys AG	Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
AU2016228249A1 (en)	2006-09-26	2016-10-06	Genmab A/S	Combination treatment of CD38-expressing tumors
EP1914242A1 (en) *	2006-10-19	2008-04-23	Sanofi-Aventis	Novel anti-CD38 antibodies for the treatment of cancer
AU2013209322A1 (en)	2006-10-19	2013-08-15	Sanofi-Aventis	Novel anti-cd38 antibodies for the treatment of cancer
KR101552735B1 (ko) *	2006-12-01	2015-09-14	메다렉스, 엘.엘.시.	씨디22에 결합하는 인간 항체 및 이의 용도
CN101605906A (zh)	2006-12-14	2009-12-16	梅达雷克斯公司	结合cd70的人类抗体及其用途
KR20090088946A (ko)	2006-12-14	2009-08-20	메다렉스, 인코포레이티드	씨디70에 결합하는 인간 항체 및 이의 용도
CN103536915A (zh)	2006-12-27	2014-01-29	埃默里大学	用于治疗传染病和肿瘤的组合物和方法
US8691730B2 (en)	2007-09-14	2014-04-08	Adimab, Llc	Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en)	2007-09-14	2014-11-04	Adimab, Llc	Rationally designed, synthetic antibody libraries and uses therefor
AU2009301580B2 (en)	2008-10-06	2015-11-26	The University Of British Columbia	Methods and systems for predicting misfolded protein epitopes
SG178925A1 (en)	2009-09-22	2012-04-27	Volker Sandig	Process for producing molecules containing specialized glycan structures
US20120178111A1 (en) *	2009-09-23	2012-07-12	Diamandis Eleftherios P	Methods and compositions for the detection of lung cancers
DK2593594T3 (en)	2010-07-16	2017-12-11	Adimab Llc	ANTIBODY LIBRARIES
UA112170C2 (uk)	2010-12-10	2016-08-10	Санофі	Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) *	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	الأجسام المضادة لـ cd38
GB201300346D0 (en) *	2013-01-09	2013-02-20	Biolnvent Internat Ab	BiologIcal materials and uses thereof
GB201302447D0 (en)	2013-02-12	2013-03-27	Oxford Biotherapeutics Ltd	Therapeutic and diagnostic target
EP2970471A2 (en)	2013-03-15	2016-01-20	F. Hoffmann-La Roche AG	Anti-crth2 antibodies and their use
JP2017506640A (ja)	2014-02-14	2017-03-09	セントローズ，エルエルシー	細胞外標的化薬物共役体
JP6775422B2 (ja)	2014-03-28	2020-10-28	ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、Ｉｎｃ．	Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
MA40894A (fr)	2014-11-04	2017-09-12	Glenmark Pharmaceuticals Sa	Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
WO2016089862A1 (en)	2014-12-01	2016-06-09	The Trustees Of The University Of Pennsylvania	Dna antibody constructs and method of using same
ES2927119T3 (es)	2015-04-08	2022-11-02	Sorrento Therapeutics Inc	Productos terapéuticos de anticuerpos que se unen a CD38
GB201506389D0 (en)	2015-04-15	2015-05-27	Berkel Patricius H C Van And Howard Philip W	Site-specific antibody-drug conjugates
HRP20240338T1 (hr)	2015-06-24	2024-05-24	Janssen Biotech, Inc.	Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
CA2997444A1 (en)	2015-09-29	2017-04-06	Amgen Inc.	Asgr inhibitors for reducing cholesterol levels
PE20240096A1 (es)	2015-10-02	2024-01-18	Hoffmann La Roche	Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
KR102719065B1 (ko)	2017-06-08	2024-10-17	블랙 벨트 테라퓨틱스 리미티드	Cd38 조정 항체
US12590171B2 (en) *	2019-09-27	2026-03-31	Nanjing GenScript Biotech Co., Ltd.	Anti-VHH domain antibodies and use thereof

2018
- 2018-06-08 KR KR1020207000253A patent/KR102719065B1/ko active Active
- 2018-06-08 CA CA3066553A patent/CA3066553A1/en active Pending
- 2018-06-08 US US16/620,589 patent/US12343394B2/en active Active
- 2018-06-08 EP EP18731394.5A patent/EP3635002A1/en active Pending
- 2018-06-08 WO PCT/EP2018/065243 patent/WO2018224685A1/en not_active Ceased
- 2018-06-08 CN CN201880049993.8A patent/CN110997722B/zh active Active
- 2018-06-08 AU AU2018280871A patent/AU2018280871B2/en active Active
- 2018-06-08 WO PCT/EP2018/065239 patent/WO2018224683A1/en not_active Ceased
- 2018-06-08 AU AU2018280869A patent/AU2018280869B2/en active Active
- 2018-06-08 KR KR1020257004706A patent/KR20250025514A/ko active Pending
- 2018-06-08 US US16/621,314 patent/US12161717B2/en active Active
- 2018-06-08 JP JP2020518573A patent/JP7237951B2/ja active Active
- 2018-06-08 EP EP18731395.2A patent/EP3635003A1/en active Pending
- 2018-06-08 CA CA3066555A patent/CA3066555A1/en active Pending
- 2018-06-08 JP JP2020518572A patent/JP7237950B2/ja active Active
- 2018-06-08 CN CN201880049994.2A patent/CN110997723B/zh active Active
- 2018-06-08 KR KR1020207000247A patent/KR102770106B1/ko active Active
2022
- 2022-12-20 JP JP2022202855A patent/JP7467584B2/ja active Active
2025
- 2025-03-17 AU AU2025201908A patent/AU2025201908A1/en active Pending
- 2025-05-20 US US19/213,464 patent/US20250367286A1/en active Pending

Publication	Publication Date	Title
JP2020522280A5 (2)	2021-07-26
JP2020522281A5 (2)	2021-07-26
JP2021516973A5 (2)	2022-03-18
JP2021515568A5 (2)	2022-03-18
JP2021533726A5 (2)	2022-03-18
JP2021516974A5 (2)	2022-03-18
JP2021516975A5 (2)	2022-03-18
JP2021515565A5 (2)	2022-03-18
JP2021515566A5 (2)	2022-03-18
JP2021516976A5 (2)	2022-03-18
RU2018119165A (ru)	2019-12-19	Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
JP2021521843A5 (2)	2022-05-02
IL276830B2 (en)	2025-08-01	Anti-claudin 18.2 antibodies and uses thereof
JPWO2019175226A5 (2)	2022-03-18
JPWO2019175215A5 (2)	2022-03-18
JP2020533965A5 (2)	2021-09-24
HRP20120701T1 (hr)	2012-10-31	Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
JPWO2019175216A5 (2)	2022-03-18
JPWO2019175220A5 (2)	2022-03-18
JPWO2019175217A5 (2)	2022-03-18
CN109843927A (zh)	2019-06-04	抗b7-h3抗体、其抗原结合片段及其医药用途
JPWO2019175223A5 (2)	2022-03-18
JPWO2019175224A5 (2)	2022-03-18
JP2014524902A5 (2)	2015-07-09
JP2024024114A5 (2)	2024-04-02